<DOC>
	<DOCNO>NCT00490685</DOCNO>
	<brief_summary>The aim study evaluate , radiological progression , efficacy patient treat Sorafenib dose 600 mg bid compare patient treat best supportive care . Primary efficacy objective progression free survival randomization .</brief_summary>
	<brief_title>Dose Escalation Sorafenib Patients With Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients advanced/inoperable HCC eligible radical locoregional therapy Male female patient ≥ 18 year age Life expectancy least 12 week screen Histologically cytologically document HCC At least one tumor lesion meet follow criterion : 1 . The lesion measurable per RECIST criterion , 2 . The lesion subject previous locoregional therapy ( radiation therapy , TACE , TAE , PEI , RFA , cryoablation ) Patients previously treat locoregional treatment eligible provide previously treat lesion select target lesion . Local therapy must complete least 4 week prior baseline scan ECOG PS 0 , 1 , 2 Cirrhotic status ChildPugh class A B BarcelonaClinic Liver Cancer ( BCLC ) stage B C The following laboratory parameter : Platelet count ≥ 60 x 109 /L Haemoglobin ≥ 8,5 g/dL Total bilirubin ≤ 3 mg/dL Alanine transaminase ( ALT ) Aspartato transaminase ( AST ) ≤ 5 x upper limit normal Amylase lipase &lt; 1,5 x upper limit normal Serum creatinine ≤ 1,5 x upper limit normal Prothrombin time ( PT ) international normalize ratio ( INR ) &lt; 2,3 PT &lt; 0,6 second control . Patients therapeutically anticoagulated agent Coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . Written inform consent prior study specific screen procedure understand patient right withdraw study time , without prejudice . Previous concurrent cancer distinct primary site histology HCC , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permit Renal failure require hemo peritoneal dialysis History cardiac disease : congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 ; active coronary artery disease ( CAD ) ; cardiac arrhythmia require antiarrhythmic therapy beta blocker ordigoxin ) , uncontrolled hypertension . Myocardial infarction 6 month prior study entry permit evidence active CAD Active clinically serious infection ( &gt; Grade 2 [ NCI CTCAE ] ) Known history human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumor include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry History organ allograft Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Patients unable swallow oral medication Any condition unstable could jeopardize safety patient his/her compliance study Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within seven day prior start study drug . Both men woman enrol trial must use adequate barrier birth control measure course trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>